Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration

References

• Decker MD, Edwards KM, Howe BJ. Combination vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Vaccines. 7th ed. PA (USA): Elsevier; 2018. p. 198–227.
   Google Scholar
• Lyseng-Williamson KM, McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexyon®/Haxacima®): a guide to its use in the primary and booster vaccination of infants and toddlers in Europe. Drugs Ther Perspect. 2013;29(11):329–335. doi:10.1007/s40267-013-0078-0.
   Google Scholar
• McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexaxim®): a review of its use in primary and booster vaccination. Paediatr Drugs. 2013;15(1):59–70. doi:10.1007/s40272-013-0007-7.
   PubMed Web of Science ®Google Scholar
• Nunes MC, Madhi SA. Review of a new fully liquid, hexavalent vaccine: hexaxim. Expert Opin Biol Ther. 2013;13(4):575–593. doi:10.1517/14712598.2013.774368.
   PubMed Web of Science ®Google Scholar
• Santos-Lima E, B’Chir S, Lane A. Combined immunogenicity data for a new DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim) following primary series administration at 2, 4, 6 months of age in Latin America. Vaccine. 2013;31(9):1255–1258. doi:10.1016/j.vaccine.2012.11.087.
   PubMed Web of Science ®Google Scholar
• WHO. WHO prequalified vaccines. 2018 [ accessed 2018 Oct 11]. https://extranet.who.int/gavi/PQ_Web/
   Google Scholar
• Plotkin SA, Liese J, Madhi SA, Ortiz E. A DTaP-IPV//PRP~T vaccine (Pentaxim): a review of 16 years’ clinical experience. Expert Rev Vaccines. 2011;10(7):981–1005. doi:10.1586/erv.11.72.
   PubMed Web of Science ®Google Scholar
• Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Hum Vaccin. 2008;4(5):328–340.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Voelker R, Santos-Lima E, Zambrano B. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine. 2010;28(20):3595–3601. doi:10.1016/j.vaccine.2010.02.049.
   PubMed Web of Science ®Google Scholar
• Baldo V, Bonanni P, Castro M, Gabutti G, Franco E, Marchetti F, Prato R, Vitale F. Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b vaccine; Infanrix™ hexa. Hum Vaccin Immunother. 2014;10(1):129–137. doi:10.4161/hv.26269.
   PubMed Web of Science ®Google Scholar
• Dhillon S. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa): A review of its use as primary and booster vaccination. Drugs. 2010;70(8):1021–1058. doi:10.2165/11204830-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines. 2009;8(6):663–678. doi:10.1586/erv.09.32.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Yildirim I, Tezer H, Devrim I, Feroldi E. 2017. A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Turkish infants and toddlers. Turkish J Med Sci. 47:1247–1256. doi:10.3906/sag-1609-62.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Borrow R, Da Costa X, Richard P, Eymin C, Boisnard F, Lockhart S. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. Vaccine. 2017;35(3):452–458. doi:10.1016/j.vaccine.2016.11.053.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Lalwani S, Vidor E. Immunogenicity and safety of a liquid hexavalent vaccine in Indian infants. Indian Pediatr. 2017;54:15–20.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Mitha I, Cutland C, Groome M, Santos-Lima E. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J. 2011;30(4):e68–74. doi:10.1097/INF.0b013e31820b93d2.
   PubMed Web of Science ®Google Scholar
• Aquino AG, Brito MG, Doniz CE, Herrera JF, Macias M, Zambrano B, Plennevaux E, Santos-Lima E. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children. Vaccine. 2012;30(45):6492–6500. doi:10.1016/j.vaccine.2012.07.040.
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis. 2011;15(4):e249–56. doi:10.1016/j.ijid.2010.12.004.
   PubMed Web of Science ®Google Scholar
• Lanata C, Zambrano B, Ecker L, Amemiya I, Gil A, Santos-Lima E. 2012. Immunogenicity and safety of a fully liquid DTaP-IPV-Hep B-PRP-T vaccine at 2-4-6 months of age in Peru. J Vaccines Vaccin. 3:128. doi:10.4172/2157-7560.1000128.
   Google Scholar
• López P, Mohs A, Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B. A randomized, controlled study of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccinations of healthy infants and toddlers in Latin America. Pediatr Infect Dis J. 2017;36(11):e272–e82. doi:10.1097/INF.0000000000001682.
   PubMed Web of Science ®Google Scholar
• Macias M, Lanata CF, Zambrano B, Gil AI, Amemiya I, Mispireta M, Ecker L, Santos-Lima E. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatr Infect Dis J. 2012;31(8):e126–32. doi:10.1097/INF.0b013e318258400d.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J. 2011;30(6):e88–96. doi:10.1097/INF.0b013e318212eb80.
   PubMed Web of Science ®Google Scholar
• Vesikari TS, Silfverdal SA, Jordanov E, Feroldi E. A randomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3, 5 and 11-12 month schedule. Pediatr Infect Dis J. 2017;36(1):87–93. doi:10.1097/INF.0000000000001358.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Diez-Domingo J, Feroldi E, Jordanov E, B’Chir S, Da Costa X. Evaluation of a hexavalent-pentavelent-hexavalent infant primary vaccination series followed by a pentavalent booster vaccine in infants and toddlers. Pediatr Inf Dis J. 2018 (in press). doi:10.1097/INF.0000000000002231
   Google Scholar
• Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013;32(8):889–897. doi:10.1097/INF.0b013e318292f7b1.
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Chokephaibulkit K, Benjaponpitak S, Pancharoen C, Chuenkitmongkol S, B’Chir S, Da Costa X, Vidor E. Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP~T vaccination at 2, 4 and 6 months. Hum Vaccin Immunother. 2018;14(5):1257–1265. doi:10.1080/21645515.2018.1426418.
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine. 2010;28(3):730–736. doi:10.1016/j.vaccine.2009.10.074.
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, Crasta PD, Messier M, Hardt K. Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand. Hum Vaccin Immunother. 2013;9(8):1679–1684. doi:10.4161/hv.24844.
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Crasta PD, Hardt K. Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers. Hum Vaccin Immunother. 2012;8(7):896–904. doi:10.4161/hv.19989.
   PubMed Web of Science ®Google Scholar
• Van Der Meeren O, Behre U, Crasta P. Immunity to hepatitis B persists in adolescents 15-16 years of age vaccinated in infancy with three doses of hepatitis B vaccine. Vaccine. 2016;34(24):2745–2749. doi:10.1016/j.vaccine.2016.04.013.
   PubMed Web of Science ®Google Scholar
• Van Der Meeren O, Bleckmann G, Crasta PD. Immune memory to hepatitis B persists in children aged 7-8 years, who were vaccinated in infancy with 4 doses of hexavalent DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine. Hum Vaccin Immunother. 2014;10(6):1682–1687. doi:10.4161/hv.28480.
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis B vaccines: WHO position paper - July 2017. Wkly Epidemiol Rec. 2017;92(27):369–392.
   PubMedGoogle Scholar
• Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857–872.
   PubMed Web of Science ®Google Scholar